Iambic Therapeutics

Iambic Therapeutics combines physics-informed machine learning with generative AI to accelerate small molecule drug discovery. The company's NeuralPLexer platform integrates protein language models with molecular encoders informed by physical principles, enabling identification of lead compounds in as little as 5 months. Iambic has advanced two AI-discovered oncology candidates toward the clinic: IAM-H1 (HER2 inhibitor) and IAM-C1 (dual CDK2/4 inhibitor).

$250M+

Total raised

NeuralPLexer is a physics-informed ML platform that combines protein language models with graph-based molecular encoders. The integration of physical principles improves data efficiency and allows exploration across broad chemical space, enabling identification of lead compounds in as little as 5 months.